Pharmaceutical-grade, Radiopaque Perflubron

Intended Use: Liquivent is intended to be used as an aid in removing debris, secretions, and foreign matter from the lungs via bronchoalveolar lavage (BAL).

Registration

CE Marked.

USA: For Research Use Only.

For availability in your country, please contact your local distributor or connect with your distributor below.

  • Bioinert

    The molecules of Liquivent,  a Perfluorocarbon (PFCs) called Perflubron (PFOB), are too large to be metabolized3. PFOB is bioinert, immiscible with other liquids, minimally absorbed4, and has no deleterious histological cellular or biochemical effects1.
  • Effective

    Due to Perflubron’s high density and low viscosity, most liquids and solids float on top of it. This allows toxic, damaging exudates as well as infectious material to float to the top, where they can be removed using suction5.
  • Respiratory Advantages

    Does not block oxygen transfer during lavage6 or elicit a cough reflex. Improves lung function, reduces inflammation7, and enhances surfactant phospholipid production2.
  • Available in Syringes and Vials

    Liquivent is available in either a syringe or vial. Choose the option that works best for your hospital.

ML28.R02

Product Use

Product Code Product Description Stock/Non-Stock
PFB-3 3cc in a 10 cc vial containing Perflubron Non-Stock
PFB-50* 50cc syringe containing Perflubron Stock

 

Stock items are produced regularly and when available ship within 3 business days. Non-stock items take 16-20 weeks to produce with a required minimum order quantity.

* Unavailable until October 2022.

What is the intended use?

Liquivent is for research use only in the USA. The CE-approved intended use is as an aid in removing debris, secretions, and foreign matter from the lungs via bronchoalveolar lavage (BAL).

How quickly does it evaporate?

While it does evaporate, there will be residual Perflurobron left in the lungs that should be suctioned out. When used for bronchial lavage, it is instilled into the lungs and suctioned back out.

What is a normal dosage?

10-20cc/kg for bronchial lavage.

How do I access Liquivent for research purposes?

Please contact customer service at 512-474-7878, submit a quote request form, or email info@origen.com for pricing and availability.

What is the expiration date of Liquivent Products?

3 years

I have a problem with a product, what is the complaint procedure?

Please report it as soon as possible. Contact the OriGen head office or your sales representative. Please retain the product and its packaging as this will help us in our investigation and findings. All complaints will receive a written or oral response acknowledging receipt of the product and initial findings.

Where can I find the Instructions for Use (IFU) or Certificate of Analysis (CoA) for the product I received?

An IFU and CoA will be in your original shipment box. If these items are misplaced, you can access the IFU and CoA for your OriGen products through the Client Login. If you do not have a current login, you will need to register for an account through that page.

1. Reickert C, Praniko_ T, Overbeck M, Kazerooni E, Massey K, Bartlett R, Hirschl R. “The Pulmonary And Systemic Distribution And Elimination Of Perflubron From Adult Patients Treated With Partial Liquid Ventilation” Chest. 2001 Feb; 119(2):515-522.

2. Steinhorn DM, Leach CL, Fuhrman BP, Holm BA. “Partial Liquid Ventilation Enhances Surfactant Phospholipid Production.” Critical Care Med. 1996 Jul; 24(7):1252-6.

3. Flaim SF. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Substit Immobil Biotechnol. 1994;22(4):1043-54. doi: 10.3109/10731199409138801. PMID: 7849908.

4. Broaddus, V. C., Ernst, J. D., King, T. E., Lazarus, S. C., Sarmiento, K. F., Schnapp, L. M., Stapleton, R. D., & Gotway, M. B. (2022). Murray & Nadel’s textbook of Respiratory Medicine (7th ed.). Elsevier.

5. Farnham, RRT, Bill. “An American Perspective.” RT Magazine, 7 Feb. 2007, https://rtmagazine.com/disorders-diseases/critical-care/ards/an-american-perspective/.

6. Patankar, Nikhil; Al-Ibrahim, Omar 716, Critical Care Medicine: December 2015 – Volume 43 – Issue 12 – p 180. doi: 10.1097/01.ccm.0000474544.58195.50.

7. Haeberle H. A., Nesti F., Dieterich H.-J., Gatalica Z., Garofalo R. P. (2002). Perflubron Reduces Lung Inflammation in Respiratory Syncytial Virus Infection by Inhibiting Chemokine Expression and Nuclear Factor-˜B Activation. Am. J. Respir. Crit. Care Med. 165, 1433–1438. Doi:10.1164/rccm.2109077.

Liquivent® is a registered trademark of OriGen Biomedical, Inc.

Interested in Custom Product Development?

Learn more about the custom product development process by clicking below.

Learn More